An interventional study of Digital self-management program in Breast Cancer, Colorectal Cancer (CRC) and Prostate Cancer, sponsored by Mälardalen University. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Mälardalen University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Summary
Reducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment. Therefore, the goal of this project is with a multicenter randomised controlled design investigate whether a digital support intervention during ongoing neo- or adjuvant cancer treatment for breast, prostate or colon cancer is effective in reducing sedentary lifestyle and improving well-being in the short and long term.
Description of the project
This project is about investigating the effect of a digital support intervention to reduce sedentary behavior in people with breast, prostate, or colorectal cancer during neo- or adjuvant cancer treatment. The digital support intervention has been developed with patients and researchers and consists of existing high-quality technology that provides support for setting and following goals. The people who use the digital support intervention also receive support from a physiotherapist to set goals for reduced sedentary time and get to choose which activities will replace the time spent sedentary.
The goal of the project
The goal of the project is to investigate the effects of a digital support intervention on reduced sedentary and well-being during ongoing cancer treatment, both in the short and long term. In addition, the project will study the health-economic effects, and climate benefits of using the digital support intervention. By focusing on reducing a sedentary lifestyle and replacing it with daily activities and/or physical activity, the health of individuals is expected to be positively affected in the short term through, for example, increased well-being and reduced side effects from cancer treatment, and the long term through a reduced risk of developing complications and new illness related to the cancer treatment, such as cardiovascular disease.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
This study's planned enrollment of 210 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Mälardalen University is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a digital support intervention
Behavioral: Digital self-management program
Control condition. Individuals receive the care as usual provided by the healthcare only.
The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.
Sedentary behavior time
The Axivity accelerometer is used for measuring the primary outcome of sedentary time, i.e. mean time spent in sedentary behavior/day.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.
Sedentary behavior bouts
The Axivity accelerometer is used for measuring sedentary bouts, i.e. mean number of bouts/day and mean bouts time/day.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.
Physical activity
The Axivity accelerometer is used for measuring physical activity mean time/day and mean time spent in low-, moderate and high intensity physical activity.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.
Health-related quality of life
Patient reported health related quality of life will be assessed with European Organization for Research and Treatment of Cancer QLQ C 30 and diagnose specific modules BR23, PR26 and CR29.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Health-related quality of life
Patient reported health related quality of life will be assessed with EQ5D, and used for calculation of Quality Adjusted Life Years.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Cancer related fatigue
Patient reported outcome cancer related fatigue is measured with Brief Fatigue Inventory.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Fear of movement
Patient reported outcome Fear of movement is assessed with Cancer specific Tampa Scale for Kinesiophobia.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Changes in health
Patient reported outcome Changes in health is assessed with Patient Global Impression of Change Scale.
Time frame: At 3-months, 6 months, 12 months and 24 months.
Work ability
Selected and adapted questions from Work Ability Index are used for assessing patient reported outcome work ability.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Self-efficacy for reducing sedentary behavior
Study specific question is used for assessing patient reported outcome of Self-efficacy for reducing sedentary behavior.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Perceived support from peers
Study specific question is used for assessing patient reported outcome of Perceived support from peers.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Demographic variables
Study specific questions
Time frame: Baseline
Diagnoses
Data regarding cancer diagnose and if any, co-morbid conditions, are gathered from medical records or Swedish national quality registers.
Time frame: At baseline
Cancer treatment
Data regarding planned and received oncological and surgical cancer treatment (type, dose, treatment start and end date of treatment) and any treatment related side-effects are gathered from medical records and Swedish quality registers.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Health care costs
Data regarding outpatient visits, hospitalization and prescribed medication is gathered from Swedish national quality registers.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Costs of intervention
Data regarding cost of application use and any cost for physical activity is gathered from study records and patient reported by study specific questions.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Sick leave
Data regarding sick leave, i.e. total number of days being on sick leave gathered from the Swedish insurance fund (data on sick leave more than 14 days) and patient reported study specific questions (data on sick leave less than 14 days). Data will be gathered from 6 months prior baseline (study specific questions are administered at baseline and register data will be gathered at baseline but will include any data 6 months prior baseline).
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Adherence
Adherence to the intervention is assessed by Axivity accelometer and patient reported study specific questions.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Green house gas emissions
Green house emissions will be compared between the intervention and control group and estimated using a life cycle analysis of the technology used in the intervention, self-reported changes in climate behavior, and emissions from healthcare.
Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.
Plan to share: No — Individual medical information may not be shared with other researchers if the research questions are not within the scope of the current approved Swedish Ethical Review Board application (and any amendments) for this research. Only pseudonymous information may be shared after approval has been provided from the Swedish Ethical Review Board.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2029, 57 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 57 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mälardalen University